mRNA CDMO Services Market
完整報告名稱與涵蓋範圍
mRNA CDMO Services Market Size, Share & Trends Analysis Report, By Service Type (Plasmid and DNA Template Manufacturing, In Vitro Transcription and Drug Substance Manufacturing, LNP Formulation and Drug Product Manufacturing, Analytical Development and Release Testing, Regulatory and Clinical Supply Services), By RNA Modality (Conventional mRNA, Self-Amplifying RNA, Circular RNA and Other Novel Formats), By Scale (Preclinical and Clinical, Commercial), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The mRNA CDMO services market covers outsourced manufacturing of messenger RNA and related modalities, including plasmid and enzymatic DNA template production, in vitro transcription and purification of drug substance, lipid nanoparticle formulation and drug product filling, analytical development and release testing and regulatory and clinical supply support, for conventional, self-amplifying and circular RNA. Captive manufacturing by RNA originators and the supply of raw materials such as enzymes and nucleotides are excluded.
The customer base has broadened from pandemic vaccine supply to a pipeline of infectious disease and cancer vaccines, protein replacement, in vivo gene editing and in vivo cell therapy programs, many run by companies without manufacturing infrastructure. Providers differentiate through integrated template-to-drug-product offerings, GMP capacity for gram-scale drug substance, expertise in capping and purification for low double-stranded RNA content, closed and automated small-batch platforms for personalised cancer vaccines and capabilities for self-amplifying and circular formats. The post-pandemic capacity overhang has consolidated the provider base, and sponsors now favour partners with commercial track records and flexible batch sizes.
North America and Europe host the leading providers, while South Korea, Japan, China and Singapore have built capacity supported by government programs. Competition involves nucleic acid manufacturing specialists, integrated biologics CDMOs and RNA originators offering contract capacity.
The InsightAce study provides US$ revenue forecasts for every service type, RNA modality, scale and end user and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global mRNA CDMO Services Market Snapshot
Chapter 4. Global mRNA CDMO Services Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Service Type Estimates & Trend Analysis
5.1. Service Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Service Type:
5.2.1. Plasmid and DNA Template Manufacturing
5.2.2. In Vitro Transcription and Drug Substance Manufacturing
5.2.3. LNP Formulation and Drug Product Manufacturing
5.2.4. Analytical Development and Release Testing
5.2.5. Regulatory and Clinical Supply Services
Chapter 6. Market Segmentation 2: By RNA Modality Estimates & Trend Analysis
6.1. RNA Modality & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by RNA Modality:
6.2.1. Conventional mRNA
6.2.2. Self-Amplifying RNA
6.2.3. Circular RNA and Other Novel Formats
Chapter 7. Market Segmentation 3: By Scale Estimates & Trend Analysis
7.1. Scale & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Scale:
7.2.1. Preclinical and Clinical
7.2.2. Commercial
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Pharmaceutical Companies
8.2.2. Biotechnology Companies
8.2.3. Government and Non-Profit Sponsors
Chapter 9. mRNA CDMO Services Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Aldevron (Danaher)
11.2. TriLink BioTechnologies (Maravai LifeSciences)
11.3. Lonza Group AG
11.4. ST Pharm Co., Ltd.
11.5. Kaneka Eurogentec S.A.
11.6. eTheRNA Manufacturing
11.7. Samsung Biologics Co., Ltd.
11.8. Novo Nordisk A/S (Catalent)
11.9. Thermo Fisher Scientific Inc.
11.10. Recipharm AB
11.11. BioNTech SE (Contract Capacity)
11.12. Quantoom Biosciences
11.13. Vernal Biosciences
11.14. Curia Global, Inc.
11.15. WuXi Biologics (Cayman) Inc.
圖表清單 List of Tables & Figures
Table 1. Global mRNA CDMO Services Market Revenue Forecast by Service Type, 2026-2035 (US$ Mn)
Figure 1. Global mRNA CDMO Services Market Segmentation and Scope Overview
Table 2. Global mRNA CDMO Services Market Revenue Forecast by RNA Modality, 2026-2035 (US$ Mn)
Figure 2. Global mRNA CDMO Services Market Share by Service Type, 2026 & 2035
Table 3. Global mRNA CDMO Services Market Revenue Forecast by Scale, 2026-2035 (US$ Mn)
Figure 3. Integrated mRNA Manufacturing Workflow from DNA Template to Formulated Drug Product
Table 4. Global mRNA CDMO Services Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. mRNA Clinical Pipeline by Application and Its Outsourced Manufacturing Demand, 2026-2035
Table 5. Global mRNA CDMO Services Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific mRNA CDMO Services Growth Opportunity Analysis
Table 6. North America mRNA CDMO Services Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key mRNA CDMO Services Market Participants
Table 7. Europe mRNA CDMO Services Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global mRNA CDMO Services Market
Table 8. Asia Pacific mRNA CDMO Services Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Post-Pandemic mRNA Manufacturing Capacity Rebalancing by Provider and Region
Table 9. Strategic Developments of Leading mRNA CDMO Services Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們